

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau




INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 6 : C12N 15/86, 7/01		A1	(11) International Publication Number: WO 98/10088
			(43) International Publication Date: 12 March 1998 (12.03.98)
(21) International Application Number: PCT/US97/15716		(74) Agents: KODROFF, Cathy, A. et al.; Howson and Howson, Spring House Corporate Center, P.O. Box 457, Spring House, PA 19477 (US).	
(22) International Filing Date: 4 September 1997 (04.09.97)			
(30) Priority Data: 60/024,699 6 September 1996 (06.09.96) US		(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).	
(60) Parent Application or Grant (63) Related by Continuation US 60/024,699 (CON) Filed on 6 September 1996 (06.09.96)		Published With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.	
(71) Applicant (for all designated States except US): TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA [US/US]; Suite 300, 3700 Market Street, Philadelphia, PA 19104-3147 (US).			
(72) Inventors; and (75) Inventors/Applicants (for US only): WILSON, James, M. [US/US]; 1350 N. Avignon Drive, Galdwyne, PA 19035 (US). CHEN, Nancie [CN/US]; Apartment C5, 174 S. Bethlehem Pike, Ambler, PA 19002 (US).			

(54) Title: AN INDUCIBLE METHOD FOR PRODUCTION OF RECOMBINANT ADENO-ASSOCIATED VIRUSES UTILIZING T7 POLYMERASE

(57) Abstract

Methods for efficient production of recombinant AAV are described. In one aspect, three vectors are introduced into a host cell. A first vector directs expression of T7 polymerase. A second vector carries rep and cap under the control of the T7 promoter. A third vector contains a rAAV cassette which contains a minigene flanked by AAV ITRs. In a second aspect, the host cell is stably transfected to contain a plasmid bearing one of the required vector components and the host cell is double transfected/infected.



FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

AN INDUCIBLE METHOD FOR PRODUCTION OF RECOMBINANT
ADENO-ASSOCIATED VIRUSES UTILIZING T7 POLYMERASE

Background of the Invention

Adeno-associated virus is a replication-
5 deficient parvovirus, the genome of which is about 4.6 kb
in length, including 145 nucleotide inverted terminal
repeats (ITRs). The single-stranded DNA genome of AAV
contains genes responsible for replication (rep) and
formation of virions (cap).

10 When this nonpathogenic human virus infects a
human cell, the viral genome integrates into chromosome
19 resulting in latent infection of the cell. Production
of infectious virus and replication of the virus does not
occur unless the cell is coinfecting with a lytic helper
15 virus such as adenovirus or herpesvirus. Upon infection
with a helper virus, the AAV provirus is rescued and
amplified, and both AAV and helper virus are produced.

AAV possesses unique features that make it
attractive as a vector for delivering foreign DNA to
20 cells. Various groups have studied the potential use of
AAV in the treatment of disease states.

However, an obstacle to the use of AAV for
delivery of DNA is the lack of highly efficient methods
for encapsidation of recombinant genomes. See, R. Kotin,
25 Hum. Gene Ther., 5:793-801 (1994). Furthermore, the rep
gene product is toxic to cells and thus cannot be
expressed at high levels. For example, previously known
methods employ transfection of host cells with a rAAV
genome which lacks rep and cap genes followed by co-
30 infection with wild-type AAV and adenovirus. However,
this method leads to unacceptably high levels of wild-
type AAV. Incubation of cells with rAAV in the absence
of contaminating wild-type AAV or helper adenovirus is
associated with little recombinant gene expression. And,
35 in the absence of the AAV rep gene product, integration
is inefficient and not directed to chromosome 19.

Bacteriophage T7 RNA polymerase (T7 Pol) is the product of T7 gene 1, which can recognize its responsive promoter sequence specifically and exhibit a high transcriptase activity [M. Chamberlin et al, Nature, 5 228:227-231 (1970); J. Dunn and F. Studier, J. Mol. Biol., 166:447-535 (1983); and B. Moffatt et al, Cell, 49:221-227 (1987)]. It has been used for heterologous expression of proteins in *E. coli* [S. Tabor and C. Richardson, Proc. Natl. Acad. Sci. USA, 82:1074-1078 10 (1985); F. Studier and B. Moffatt, J. Mol. Biol., 189:113-130 (1986)], in recombinant vaccinia virus-infected eukaryotic cells [T. Fuerst et al, Proc. Natl. Acad. Sci. USA, 83:8122-8126 (1986); A. Ramsey-Ewing and B. Moss, J. Biol. Chem., 271:16962-16966 (1996)], and in 15 mammalian cells [A. Lieber et al, Nucl. Acids Res., 17:8485-8493 (1989)].

What is needed is an efficient method for production of rAAV which avoids the problems associated with rep toxicity for the packaging cell.

20 Summary of the Invention

The present invention provides an inducible method for efficient production of rAAV which makes use of T7 polymerase. T7 Pol is derived from lambda phage and its promoter is not active in mammalian cells. Thus, 25 expression of rep/cap can be controlled by placing these genes under control of the T7 promoter and providing the T7 Pol in trans or under the control of an inducible promoter. Thus, this method avoids the toxic effects of rep which rendered prior art methods of producing rAAV 30 inefficient. The method of the invention is particularly suitable for large scale production of rAAV, which is desired for rAAV vectors to be used in gene therapy.

In one aspect, the invention provides a method of producing rAAV which utilizes three vectors. A first

vector is capable of expressing T7 polymerase in the host cell following transfection or infection. A second vector comprises the AAV *rep* and *cap* genes under the control of T7 promoter sequences (T7/*rep/cap*). The third
5 vector comprises a cassette containing 5' and 3' AAV inverted terminal repeats (ITRs) flanking a selected transgene. A host cell containing these three vectors is cultured under conditions which permit replication and packaging of a recombinant AAV, and the rAAV is
10 recovered.

In another aspect, the invention provides a method in which a host cell is stably transfected with one of the three components of the system used in the triple infection system. The remaining components are
15 introduced into the host cell, as described above.

In one embodiment, the invention provides method in which a vector containing T7/*rep/cap* and a vector containing a cassette comprising a selected minigene flanked by 5' and 3' AAV ITRs are introduced
20 into a host cell expressing T7 polymerase. The host cell is then cultured under conditions which permit production of rAAV. In another embodiment, this invention provides a method which utilizes a host cell stably transfected with a plasmid containing T7/*rep/cap*. A vector
25 containing T7 *pol* and a vector containing a cassette comprising 5' AAV inverse terminal repeat (ITR), a selected minigene, and 3' AAV ITR are introduced into the host cell. The host cell is cultured under conditions which permit production of rAAV. In still another
30 embodiment, the invention provides a method which utilizes a host cell stably transfected with a rescuable rAAV cassette. A vector containing T7 *pol* and a vector containing T7/*rep/cap* are introduced into the host cell. The host cell is cultured under conditions which permit
35 production of rAAV.

In yet another aspect, the present invention provides a method which utilizes a host cell stably transfected with two of the three components of the system used in the triple infection system. The
5 remaining component is then introduced into the host cell, as described above.

In a further aspect, the present invention provides a method which utilizes a host cell stably transfected with the three components of the system used
10 in the triple infection system. In this aspect, the T7 Pol is controlled by an inducible promoter.

In still a further aspect, the invention provides a rAAV produced according to the method of the invention.

15 Other aspects and advantages of the present invention are described further in the following detailed description of the preferred embodiments thereof.

Brief Description of the Drawings

Fig. 1 provides a schematic illustration of the
20 construction of a recombinant adenovirus containing the T7 polymerase gene.

Fig. 2 provides a schematic illustration of the construction of a recombinant plasmid containing the AAV rep/cap genes under control of a T7 promoter.

25 Fig. 3 provides a schematic illustration of the construction of a recombinant adenovirus containing the rep/cap genes under control of a T7 promoter.

Fig. 4 provides a schematic illustration of the construction of a recombinant hybrid Ad/AAV virus.

30 Detailed Description of the Invention

The invention provides an inducible method for efficient production of recombinant AAV vectors useful particularly for gene delivery and transfer.

Specifically, the invention provides methods of AAV production in which expression of the toxic but necessary rep gene is controlled by the T7 promoter.

Thus, in one aspect, the method of the invention for production of rAAV involves introducing into a host cell the AAV rep and cap genes under control of a T7 promoter, and a recombinant adeno-associated virus (rAAV) cassette containing a selected minigene flanked by AAV ITRs. Upon introduction of a gene encoding T7 pol, high level expression of rep protein from the T7/rep/cap construct is induced and cells may be grown on a large scale. When rep expression is desired, the cells are caused to express the T7 polymerase which acts on the T7 promoter. This facilitates the efficient replication and packaging of rAAV carrying a gene of interest.

A host cell may be triple transfected (or infected) with vectors containing the above elements. Alternatively, a host cell which expresses one or more of the required elements and may be transfected/infected with the remaining elements is utilized. In another alternative, a host cell is utilized which stably expresses all three elements of the system, and the T7 pol is placed under the control of an inducible promoter, which permits rep/cap expression to be controlled and the avoidance of toxic effects to the cell.

For each of the vector components used in the method of the invention, adenoviral constructs are currently preferred. However, using the information provided herein and known techniques, one of skill in the art could readily construct a different viral (adenoviral or non-adenoviral) or a plasmid vector which is capable of driving expression of the desired genes in the host cell. For example, although less preferred because of their inability to infect non-dividing cells, vectors

carrying the required elements of this system, e.g., the T7 polymerase, may be readily constructed using retroviruses. Therefore, this invention is not limited by the virus or plasmid selected for purposes of introducing the T7 pol, T7/rep/cap, or AAV cassette into the host cell. Desirably, at least one of the vectors is a virus which provides the necessary helper functions to enable packaging. Alternatively, the helper functions may be provided by a co-transfected adenovirus or herpesvirus. Suitable techniques for introducing these vectors into the host cell are discussed below and are known to those of skill in the art. As used herein, a "host cell" is any cell (cell line), preferably mammalian, which permits expression of the T7 pol and T7/rep/cap and packaging of the rAAV containing the cassette, under the conditions described herein. Suitable packaging cells are known, and may be readily selected by the skilled artisan.

A. *Triple Infection/Transfection*

As stated above, a host cell used for assembly and packaging of recombinant AAV may be transfected with plasmid vectors or infected with viral vectors containing the required components of the system.

1. *T7 Pol Vectors*

In a preferred embodiment, a first vector contains the T7 Pol gene under the control of a suitable promoter. In example 5 below, the nuclear localized T7 Pol gene is obtained from a publicly available plasmid [M. Strauss, Nucleic Acid Res., 17:8485-8493 (1989)]. However, the gene may alternatively be obtained from other commercial and academic sources, including the American Type Culture Collection (pTF7-3, Accession No. 484944). See, also GenBank accession number M30308. Desirably, the T7 pol

gene is linked to a nuclear localization signal, such as that described in Dunn, Gene, 68:259-266 (1988), using conventional techniques.

Desirably, T7 Pol is under the control of a cytomegalovirus (CMV) immediate early promoter/enhancer [see, e.g., Boshart et al, Cell, 41:521-530 (1985)]. However, other suitable promoters may be readily selected by one of skill in the art. Useful promoters may be constitutive promoters or regulated (inducible) promoters, which will enable control of the amount of the transgene to be expressed. For example, another suitable promoter includes, without limitation, the Rous sarcoma virus LTR promoter/enhancer. Still other promoter/enhancer sequences may be selected by one of skill in the art.

In addition, the vector also includes other conventional regulatory elements necessary to drive expression of T7 Pol in a cell transfected with the vector. Such regulatory elements are known to those of skill in the art.

2. T7/Rep/Cap Vectors

The second vector component of this system contains the *rep* and *cap* genes under control of a T7 promoter. The *rep* and *cap* genes can be obtained from a variety of known sources. See, e.g., T. Shenk, J. Virol., 61:3096-3101 (1987), which provides the AAV2 genome within the plasmid psub201; E. W. Lusby et al, J. Virol., 41:518-526 (1982) and J. Smuda and B.J. Carter, Virology, 184:310-318 (1991).

Similarly, the T7 promoter sequences [J. J. Dunn and F.W. Studier, J. Mol. Biol., 166:477-535 (1983)] may be obtained from a variety of commercial and academic sources. In a preferred embodiment, the vector further contains the sequence of untranslated region (UTR) of encephalomyocarditis (EMCV) downstream of the T7

promoter. The inventors believe this sequence increases expression of the gene 5- to 10-fold.

In addition, the vector also includes conventional regulatory elements necessary to drive
5 expression of the rep/cap in a cell transfected with the vector. Such regulatory elements are known to those of skill in the art.

3. rAAV Cassette (Template)

The third vector component contains a
10 rAAV cassette containing a minigene flanked by AAV ITRs. As discussed in more detail below, such a minigene contains a suitable transgene, a promoter, and other regulatory elements necessary for expression of the transgene.

15 The AAV sequences employed are preferably limited to the cis-acting 5' and 3' inverted terminal repeat (ITR) sequences [See, e.g., B. J. Carter, in "Handbook of Parvoviruses", ed., P. Tijsser, CRC Press, pp.155-168 (1990)]. Desirably, substantially the
20 entire 143 bp sequences encoding the ITRs are used in the vectors. Some degree of minor modification of these sequences is expected to be permissible for this use. The ability to modify these ITR sequences is within the skill of the art. See, e.g., texts such as Sambrook et
25 al, "Molecular Cloning. A Laboratory Manual.", 2d edit., Cold Spring Harbor Laboratory, New York (1989). Alternatively, it may be desirable to use functional fragments of the ITRs. Such fragments may be determined by one of skill in the art.

30 The AAV ITR sequences may be obtained from any known AAV, including presently identified human AAV types. Similarly, AAVs known to infect other animals may also be employed in the vector constructs of this invention. The selection of the AAV is not anticipated
35 to limit the following invention. A variety of AAV

strains, types 1-4, are available from the American Type Culture Collection or available by request from a variety of commercial and institutional sources. In the following exemplary embodiment an AAV-2 is used for
5 convenience.

The 5' and 3' AAV ITR sequences flank a minigene which is made up of a selected transgene sequence and associated regulatory elements. The transgene sequence of the vector is a nucleic acid
10 sequence heterologous to the AAV sequence, which encodes a polypeptide or protein of interest. The transgene is operatively linked to regulatory components in a manner which permits transgene transcription.

The composition of the transgene
15 sequence will depend upon the use to which the resulting vector will be put. For example, one type of transgene sequence includes a reporter sequence, which upon expression produces a detectable signal. Such reporter sequences include without limitation an *E. coli* beta-galactosidase (*LacZ*) cDNA, an alkaline phosphatase gene
20 and a green fluorescent protein gene. These sequences, when associated with regulatory elements which drive their expression, provide signals detectable by conventional means, e.g., ultraviolet wavelength
25 absorbance, visible color change, etc. A more preferred transgene sequence includes a therapeutic gene which expresses a desired gene product in a host cell. These therapeutic nucleic acid sequences typically encode products which may be administered to a patient *in vivo*
30 or *ex vivo* to replace or correct an inherited or non-inherited genetic defect or treat an epigenetic disorder or disease. The selection of the transgene sequence is not a limitation of this invention.

In addition to the major elements identified above, the minigene also includes conventional regulatory elements necessary to drive expression of the transgene in a cell transfected with the vector carrying the AAV cassette. Thus the minigene contains a selected promoter which is linked to the transgene and located within the minigene, between the AAV ITR sequences of the vector.

Selection of the promoter which mediates expression of the transgene is a routine matter and is not a limitation of the vector. Useful promoters include those which are discussed above in connection with the first vector component.

The minigene will also desirably contain heterologous nucleic acid sequences including sequences providing signals required for efficient polyadenylation of the transcript and introns with functional splice donor and acceptor sites. A common poly-A sequence which is employed in the exemplary vectors of this invention is that derived from the papovavirus SV-40. The poly-A sequence generally is inserted following the transgene sequences and before the 3' AAV ITR sequence. A common intron sequence is also derived from SV-40, and is referred to as the SV-40 T intron sequence. A minigene of the present invention may also contain such an intron, desirably located between the promoter/enhancer sequence and the transgene. Selection of these and other common vector elements are conventional and many such sequences are available [see, e.g., Sambrook et al, and references cited therein].

The rAAV vector containing the AAV ITRs flanking the minigene may be carried on a plasmid backbone and used to transfect a selected host cell or may be flanked by viral sequences (e.g., adenoviral sequences) which permit it to infect the selected host

cell. Suitable Ad/AAV recombinant viruses may be produced in accordance with known techniques. See, e.g., WO 96/13598, WO 95/23867, and WO 95/06743, which are incorporated by reference herein.

5 B. *Double Infection/Transfection*

A cell line which stably expresses T7 pol may be constructed, and then double transfected (or infected) with a vector containing T7/rep/cap and a vector containing a rAAV cassette, as illustrated in the following table (Inf = infection and Txf = transfection).

	<u>T7 rep/cap</u>	<u>rAAV</u>
System A	Inf	Inf
System B	Inf	Txf
System C	Txf	Inf
15 System D	Txf	Txf

Alternatively, a cell line stably transfected with T7 rep/cap may be double transfected (infected) with a vector carrying T7 pol and a vector carrying the rAAV cassette, as illustrated in the following table.

	<u>T7 Pol</u>	<u>rAAV</u>
System E	Inf	Inf
System F	Inf	Txf
System G	Txf	Inf
25 System H	Txf	Txf

In still another alternative, a cell line which contains a rescuable rAAV cassette may be double transfected (infected) with a vector containing T7 Pol and a vector containing T7/rep/cap, as illustrated in the following table.

	<u>T7 Pol</u>	<u>T7 rep/cap</u>
System I	Inf	Inf
System J	Inf	Txf
System K	Txf	Inf
35 System L	Txf	Txf

The plasmid and viral vectors used in double transfection/infection steps are as described above in connection with the triple transfection and/or infection system.

5 A stable cell line of the invention can be produced by transfection of a desired cell, e.g., 293 cells or other packaging cell lines expressing required adenoviral genes, with a plasmid containing the desired gene, e.g., T7 Pol, using conventional techniques and
10 selected via an accompanying resistant marker gene. Depending upon whether inducible or constitutive expression is desired, an appropriate promoter may be selected. For example, if a host cell inducibly expressing T7 Pol is desired, the cell may be transfected
15 with a plasmid containing T7 Pol under control of a metallothionein promoter. Alternatively, if a host cell constitutively expressing T7 Pol is desired, it may be inserted under control of a RSV or CMV promoter. Similar techniques may be used for providing a host cell
20 containing the T7/rep/cap and a host cell containing a rescuable rAAV. The examples below describe production of stable cell lines. However, one of skill in the art could readily produce such cell lines using other conventional techniques. See, generally, Ausubel et al,
25 Current Protocols in Molecular Biology (Wiley Interscience 1987).

C. *Single Infection/Transfection*

 A cell line which stably expresses two of the components of this system may be constructed, and
30 then transfected (or infected) with a vector containing the remaining component of the system, as described above. For example, using the techniques described herein, a cell line is utilized which is stably transfected with the T7/rep/cap and a rescuable rAAV.
35 The cell line is then transfected or infected with a

vector containing the T7 pol. As another example, the cell line is stably transfected with the T7 pol and a rescuable rAAV. The cell line is then transfected or infected with a vector containing the T7 rep/cap.

5 D. *Cell Line Containing T7 Pol, rAAV and T7/rep/cap*

A cell line which stably expresses all three of the components of this system may be constructed and utilized in the method of the invention. Using known techniques, a suitable packaging cell line is constructed which contains the rAAV, the T7/rep/cap and the T7 pol. In this embodiment, the T7 Pol is placed under the control of an inducible promoter. Suitable inducible promoters are known to those of skill in the art and are discussed herein. For example, T7 Pol may be placed under control of a metallothionein promoter. In this manner, expression of the T7 Pol, and thus the rep/cap, which are under control of the T7 promoter can be regulated and toxic effects to the cell avoided.

20 E. *Production of Vectors and rAAV*

Assembly of the selected DNA sequences of the adenovirus, AAV and the reporter genes or therapeutic genes and other vector elements into the vectors described above utilize conventional techniques. Such techniques include cDNA cloning such as those described in texts [Sambrook et al, cited above], use of overlapping oligonucleotide sequences of the adenovirus or AAV genome, polymerase chain reaction, and any suitable method which provides the desired nucleotide sequence.

Whether using the three vector system, or stably infected cells, introduction of the vectors into the host cell is accomplished using known techniques. Where appropriate, standard transfection and co-transfection techniques are employed, e.g., CaPO_4

transfection techniques using the complementation human embryonic kidney (HEK) 293 cell line (a human kidney cell line containing a functional adenovirus Ela gene which provides a transacting Ela protein). Other conventional methods employed in this invention include homologous recombination of the viral genomes, plaquing of viruses in agar overlay, methods of measuring signal generation, and the like.

Following infection/transfection, the host cell is then cultured under standard conditions, to enable production of the rAAV. See, e.g., F. L. Graham and L. Prevec, Methods Mol. Biol., 7:109-128 (1991). Desirably, once the rAAV is identified using conventional techniques, it may be isolated using standard techniques and purified.

These examples illustrate the preferred methods of the invention. These examples are illustrative only and do not limit the scope of the invention.

Example 1 - Construction of a T7 Pol Adenovirus

Figure 1 provides a schematic of the construction of the recombinant adenovirus carrying the T7 polymerase.

The plasmid pMTT7N was obtained from Dr. Michael Strauss [A. Lieber et al, Nucl. Acids Res., 17:8485-8493 (1989)]. pMTT7N contains a N-terminal nuclear location signal of SV40 large T antigen fused to the T7 Pol gene (T7N Pol) which is linked to the polyadenylation sequence of SV40. Expression is driven by the inducible mouse metallothionein promoter.

The pMTT7N plasmid DNA was digested with BglII and PvuII restriction enzymes and the fragments separated on an agarose gel. The BglII/PvuII T7 Pol DNA fragment was ligated to the BglII/EcoRV cleaved vector pAd.CMV.link.1 to form pAd.CMV.T7N. pAd.CMV.link.1 is a

plasmid containing the adenoviral sequences 0 to 16 map units deleted of E1a and E1b into which a CMV promoter-polylinker cassette was cloned. This is described in X. Ye et al, J. Biol. Chem., 271:3639-3646 (1996).

In pAd.CMV.T7N, the expression unit of T7 Pol is directed by the CMV promoter. The promoter for the T7 Pol gene is linked to a PolyA tail as a cassette within the sequence of adenovirus 0-1 map unit (mu) and 9-16 mu. The pAd.CMV.T7N is linearized by Nhe I digestion and co-transfected with Cla I linearized Addel327 backbone using Cellphate kit (Pharmacia). Approximately 1 week post-transfection, the T7 Pol adenovirus can be isolated from the plaques for further purification.

15 Example 2 - Cell Lines Expressing T7 Pol

A cell line stably expressing T7 Pol is established by co-transfection of plasmids pMTT7N and pMTCB6+ (which provides a selective marker) [K. H. Choo et al, DNA, 5:529-538; Eur. J. Biochem., 174:417-424] into 293 cell at a ratio of 10:1 using calcium phosphate precipitation [F. Graham and A. van der Eb, Virology, 52:456-467 (1973)]. Colony cloning is carried out by Geneticin selection at a concentration of 1 mg/ml. Each clone obtained is transfected with pT7 rep/cap plasmid [see, Example 3 below] and analyzed for its ability to induce the expression of Rep protein upon induction by supplementation with Zn⁺⁺.

To establish a stable cell line that constitutively expresses the T7 Pol, the T7N Pol (obtained by BglIII/PvuII digestion of pMTT7N, as described above) was subcloned downstream of RSV promoter at the cloning sites of BamHI and PvuII in the vector of pEBVhis [Invitrogen]. The resulting plasmid, designated pEBVhisT7N, was transfected into 293 cells and selected

with Hygromycin at a concentration of 400 µg/ml. Each positive clone is analyzed for the presence of T7 Pol by its ability to produce expression of T7-LacZ or T7-rep/cap in cells transfected with these plasmids.

5 Example 3 - Production of T7 rep/cap Adenovirus

The production of this recombinant adenoviral vector is illustrated schematically in Figs. 2 and 3.

A. *Plasmid Construction*

10 The plasmid pTM1 [B. Moss et al, Nature, 348:91-92 (1990)], designed for expressing genes under control of the T7 promoter/EMCV UTR (untranslated region of encephalomyocarditis), was used as the vector for expressing AAV rep/cap. The entire coding sequence of rep/cap was separated into two portions by the unique
15 SacI site and subcloned into the pTM1 plasmid as described below.

Because there is no appropriate restriction enzyme existing between the initiation site of rep and its natural promoter, p5, the left end of the
20 rep sequence (N-rep) was first amplified by PCR. The sequence of the upper primer was SEQ ID NO:2: TATTTAAGCCCGAGTGAGCT (from position of 255 to 274) which introduced a nucleotide substitution A->T at position 274 (underlined). A SacI site was then generated to permit
25 the cloning of N-rep into pTM1 and in-frame expression of Rep protein from the EMCV UTR preferred initiation site (within the NcoI site). The PCR product (739 bp in length) was directly cloned into pCR2.1 vector (Invitrogen) and named pCR-N-rep.

30 The pTM-1 plasmid was digested with SacI and Stu I restriction enzymes and ligated with a 3.7 kb SacI/SnaBI fragment from psub201 [Samulski et al, J. Virol., 61:3096-3101 (1987)] containing the right end of the AAV genome (without ITR sequence), i.e., the c-

terminal portion of rep and full-length cap sequence.
This T7 promoter-driven rep/cap construct is named pT7-c-
rep/cap.

The first 535 bp sequence of rep was
5 removed from the pCR-N-Rep plasmid by SacI digestion and
subcloned into pT7-C-rep/cap, which has similarly been
digested with SacI and subjected to alkaline phosphatase
treatment to prevent self-ligation of the vector. The
final construct was named pT7 rep/cap which contains the
10 full length coding sequence of rep/cap downstream of T7
promoter/EMCV UTR, followed by the T7 terminating
sequence.

B. *Production T7 rep/cap Adenovirus*

pAd.link is a construct similar to
15 pAd.CMV.link, a plasmid containing the adenoviral
sequences 0 to 16 map units deleted of E1a and E1b as
described in the other adenovirus vectors into which a
CMV promoter-polylinker cassette was cloned and described
in X. Ye et al, J. Biol. Chem., 271:3639-3646 (1996).
20 However, pAd.link contains no CMV promoter or polyA tail
sequence.

The entire region including the T7
promoter, EMCV UTR, rep/cap and T7 terminating sequence
was excised from pT7 rep/cap by digestion with ClaI and
25 EagI, and then subcloned into the adenoviral sequences of
pAd.link, which had previously been subjected to
ClaI/SalI digestion, after filling in the sticky ends of
EagI and SalI by Klenow polymerase. The resulting
plasmid is designated pAd.T7 rep/cap.

30 The pAd.T7 rep/cap is co-transfected with
the ClaI linearized Ad.del327 backbone DNA into 293 cell
for the generation of T7 rep/cap adenovirus.

Example 4 - Cell Line Expressing rep/cap

A cell line stably transfected with pT7 rep/cap is established by transfection of pMTCB6+ into 293 cell at ratio of 10:1 and selected with Geneticin. Each clone
5 is analyzed for the presence of rep protein by transfection with T7 Pol expressing plasmid.

Example 5 - Production of Recombinant AAV Hybrid Vector

Plasmid pAV.CMVLacZ serves as a template for rAAV to be replicated and packaged in the presence of AAV
10 non-structural and capsid proteins.

Plasmid AV.CMVLacZ is a rAAV cassette in which rep and cap genes are replaced with a minigene expressing β -galactosidase from a CMV promoter. The linear arrangement of AV.CMVLacZ includes:

- 15 (a) the 5' AAV ITR (bp 1-173) obtained by PCR using pAV2 [C. A. Laughlin et al, Gene, 23: 65-73 (1983)] as template [nucleotide numbers 365-538 of SEQ ID NO:1];
- (b) a CMV immediate early enhancer/promoter [Boshart et al, Cell, 41:521-530 (1985); nucleotide
20 numbers 563-1157 of SEQ ID NO:1],
- (c) an SV40 intron (nucleotide numbers 1178-1179 of SEQ ID NO:1),
- (d) *E. coli* beta-galactosidase cDNA (nucleotide numbers 1356 - 4827 of SEQ ID NO:1),
- 25 (e) an SV40 polyadenylation signal (a 237 BamHI-BclI restriction fragment containing the cleavage/poly-A signals from both the early and late transcription units; nucleotide numbers 4839 - 5037 of SEQ ID NO:1) and
- 30 (f) 3'AAV ITR, obtained from pAV2 as a SnaBI-BglII fragment (nucleotide numbers 5053 - 5221 of SEQ ID NO:1).

Where desired, the LacZ gene can be replaced with a desired therapeutic or other transgene for the purpose of generating new rAAV. See, Fig. 4. The sequence including CMV directed LacZ reporter cassette in
5 between two AAV ITR sequences is excised from pAV.CMV.LacZ by PvuII digestion. This fragment is ligated with the EcoRV treated pAd.link to generate the plasmid pAd.AV.CMVLacZ. This plasmid is co-transfected with ClaI linearized Addel327 backbone DNA to generate an
10 adeno-rAAV hybrid virus.

Example 6 - Cell line containing rescuable, integrated rAAV template

293 cells are transfected/infected with pAV.CMVLacZ/rAAV Ad hybrid virus to generate cell line
15 that has incorporated rAAV, as determined by analysis of the genomic DNA by Southern blot. The clone is examined for the rescue of rAAV template by transfection/infection with rep/cap expressing constructs.

Numerous modifications and variations of the
20 present invention are included in the above-identified specification and are expected to be obvious to one of skill in the art. Such modifications and alterations to the processes of the present invention are believed to be encompassed in the scope of the claims appended hereto.

SEQUENCE LISTING

(1) GENERAL INFORMATION:

- (i) APPLICANT: Trustees of the University of Pennsylvania
Wilson, James M.
Chen, Nancie N.
- (ii) TITLE OF INVENTION: An Inducible Method for Production of
Recombinant Adeno-Associated Viruses Utilizing T7
Polymerase
- (iii) NUMBER OF SEQUENCES: 2
- (iv) CORRESPONDENCE ADDRESS:
 - (A) ADDRESSEE: Howson and Howson
 - (B) STREET: Spring House Corporate Cntr, PO Box 457
 - (C) CITY: Spring House
 - (D) STATE: Pennsylvania
 - (E) COUNTRY: USA
 - (F) ZIP: 19477
- (v) COMPUTER READABLE FORM:
 - (A) MEDIUM TYPE: Floppy disk
 - (B) COMPUTER: IBM PC compatible
 - (C) OPERATING SYSTEM: PC-DOS/MS-DOS
 - (D) SOFTWARE: PatentIn Release #1.0, Version #1.30
- (vi) CURRENT APPLICATION DATA:
 - (A) APPLICATION NUMBER: WO
 - (B) FILING DATE:
 - (C) CLASSIFICATION:
- (vii) PRIOR APPLICATION DATA:
 - (A) APPLICATION NUMBER: US 60/024,699
 - (B) FILING DATE: 06-SEP-1996
- (viii) ATTORNEY/AGENT INFORMATION:
 - (A) NAME: Kodroff, Cathy A.
 - (B) REGISTRATION NUMBER: 33,980
 - (C) REFERENCE/DOCKET NUMBER: GNVPN.022CIP1PCT
- (ix) TELECOMMUNICATION INFORMATION:
 - (A) TELEPHONE: 215-540-9200
 - (B) TELEFAX: 215-540-5818

(2) INFORMATION FOR SEQ ID NO:1:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 10398 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: double
 - (D) TOPOLOGY: unknown
- (ii) MOLECULE TYPE: cDNA

(x1) SEQUENCE DESCRIPTION: SEQ ID NO:1:

GAATTCGCTA GCATCATCAA TAATATACCT TATTTTGGAT TGAAGCCAAT ATGATAATGA	60
GGGGGTGGAG TTTGTGACGT GGCGCGGGGC GTGGGAACGG GGCGGGTGAC GTAGTAGTGT	120
GGCGGAAGTG TGATGTTGCA AGTGTGGCGG AACACATGTA AGCGACGGAT GTGGCAAAAG	180
TGACGTTTTT GGTGTGCGCC GGTGTACACA GGAAGTGACA ATTTTCGCGC GGTTTTAGGC	240
GGATGTTGTA GTAAATTGG GCGTAACCGA GTAAGATTG GCCATTTTCG CGGGAAAAC	300
GAATAAGAGG AAGTGAATC TGAATAATTT TGTGTTACTC ATAGCGCGTA ATATTTGTCT	360
AGGGAGATCT GCTGCGCGCT CGCTCGCTCA CTGAGGCCGC CCGGGCAAAG CCCGGGCGTC	420
GGGCGACCTT TGGTCGCCC GCCTCAGTGA GCGAGCGAGC GCGCAGAGAG GGAGTGGCCA	480
ACTCCATCAC TAGGGGTTCC TTGTAGTTAA TGATTAACCC GCCATGCTAC TTATCTACAA	540
TTGAGCTTG CATGCTGCA GGTCGTTACA TAACTTACGG TAAATGGCCC GCCTGGCTGA	600
CCGCCAACG ACCCCGCCC ATTGACGTC ATAATGACGT ATGTTCCCAT AGTAACGCCA	660
ATAGGGACTT TCCATTGACG TCAATGGGTG GAGTATTTAC GGTAACTGC CCACTTGGCA	720
GTACATCAAG TGTATCATAT GCCAAGTACG CCCCTATTG ACGTCAATGA CGGTAAATGG	780
CCCGCTGGC ATTATGCCA GTACATGACC TTATGGGACT TTCCTACTTG GCAGTACATC	840
TACGTATTAG TCATCGCTAT TACCATGGTG ATGCGGTTTT GGCAGTACAT CAATGGGCGT	900
GGATAGCGGT TTGACTCACG GGGATTTCCT AGTCTCCACC CCATTGACGT CAATGGGAGT	960
TTGTTTTGGC ACCAAAATCA ACGGGACTTT CCAAATGTC GTAACAACTC CGCCCCATTG	1020
ACGCAAATGG GCGGTAGGCG TGTACGGTGG GAGGTCTATA TAAGCAGAGC TCGTTTAGTG	1080
AACCGTCAGA TCGCCTGGAG ACGCCATCCA CGCTGTTTTG ACCTCCATAG AAGACACCGG	1140
GACCGATCCA GCCTCCGGAC TCTAGAGGAT CCGGTACTCG AGGAACTGAA AAACCAGAAA	1200
GTAACTGGT AAGTTTAGTC TTTTGTCTT TTATTTACAG TCCCGGATCC GGTGGTGGTG	1260
CAAATCAAAG AACTGCTCCT CAGTGGATGT TGCCTTTACT TCTAGGCTG TACGGAAGTG	1320
TTACTTCTGC TCTAAAAGCT GCGGAATTGT ACCCGCGGCC GCAATTCCCG GGGATCGAAA	1380
GAGCCTGCTA AAGCAAAAA GAAGTCACCA TGTCGTTTAC TTTGACCAAC AAGAACGTGA	1440
TTTTCGTTGC CGGTCTGGGA GGCATTGGTC TGGACACCAG CAAGGAGCTG CTCAAGCGCG	1500
ATCCCGTCGT TTTACAACGT CGTGACTGGG AAAACCCTGG CGTTACCCAA CTTAATCGCC	1560
TTGCAGCACA TCCCCCTTC GCCAGCTGGC GTAATAGCGA AGAGGCCCGC ACCGATCGCC	1620
CTTCCCAACA GTTGCGCAGC CTGAATGGCG AATGGCGCTT TGCCTGGTTT CCGGCACCAG	1680
AAGCGGTGCC GGAAAGCTGG CTGGAGTGGC ATCTTCCTGA GGCCGATACT GTCGTCGTCC	1740
CCTCAAAC	1800

TTACGGTCAA	TCCGCCGTTT	GTTCCCACGG	AGAATCCGAC	GGGTTGTTAC	TCGCTCACAT	1860
TTAATGTTGA	TGAAAGCTGG	CTACAGGAAG	GCCAGACGCG	AATTATTTTT	GATGGCGTTA	1920
ACTCGGCGTT	TCATCTGTGG	TGCAACGGGC	GCTGGGTCGG	TTACGGCCAG	GACAGTCGTT	1980
TGCCGTCTGA	ATTTGACCTG	AGCGCATTTT	TACGCGCCGG	AGAAAACCGC	CTCGCGGTGA	2040
TGGTGCTGCG	TTGGAGTGAC	GGCAGTTATC	TGGAAGATCA	GGATATGTGG	CGGATGAGCG	2100
GCATTTTCCG	TGACGTCTCG	TTGCTGCATA	AACCGACTAC	ACAAATCAGC	GATTTCCATG	2160
TTGCCACTCG	CTTTAATGAT	GATTTTCAGCC	GCGCTGTACT	GGAGGCTGAA	GTTTCAGATGT	2220
GCGGCGAGTT	GCGTGACTAC	CTACGGGTAA	CAGTTTCTTT	ATGGCAGGGT	GAAACGCAGG	2280
TCGCCAGCGG	CACCGCGCCT	TTCGGCGGTG	AAATTATCGA	TGAGCGTGGT	GGTTATGCCG	2340
ATCGCGTCAC	ACTACGTCTG	AACGTCGAAA	ACCCGAAACT	GTGGAGCGCC	GAAATCCCGA	2400
ATCTCTATCG	TGCGGTGGTT	GAAGTGCACA	CCGCCGACGG	CACGCTGATT	GAAGCAGAAG	2460
CCTGCGATGT	CGGTTTCCGC	GAGGTGCGGA	TTGAAAATGG	TCTGCTGCTG	CTGAACGGCA	2520
AGCCGTTGCT	GATTTCGAGGC	GTTAACCGTC	ACGAGCATCA	TCCTCTGCAT	GGTCAGGTCA	2580
TGGATGAGCA	GACGATGGTG	CAGGATATCC	TGCTGATGAA	GCAGAACAAC	TTTAACGCCG	2640
TGCGCTGTTC	GCATTATCCG	AACCATCCGC	TGTGGTACAC	GCTGTGCGAC	CGCTACGGCC	2700
TGTATGTGGT	GGATGAAGCC	AATATTGAAA	CCCACGGCAT	GGTGCCAATG	AATCGTCTGA	2760
CCGATGATCC	GCGCTGGCTA	CCGGCGATGA	GCGAACGCGT	AACGCGAATG	GTGCAGCGCG	2820
ATCGTAATCA	CCCGAGTGTG	ATCATCTGGT	CGCTGGGGAA	TGAATCAGGC	CACGGCGCTA	2880
ATCACGACGC	GCTGTATCGC	TGGATCAAAT	CTGTGATCC	TTCCCGCCCG	GTGCAGTATG	2940
AAGGCGGCGG	AGCCGACACC	ACGGCCACCG	ATATTATTTG	CCCGATGTAC	GCGCGCGTGG	3000
ATGAAGACCA	GCCCTTCCCG	GCTGTGCCGA	AATGGTCCAT	CAAAAAATGG	CTTTCGCTAC	3060
CTGGAGAGAC	GCGCCCGCTG	ATCCTTTGCG	AATACGCCCA	CGCGATGGGT	AACAGTCTTG	3120
GCGGTTTCGC	TAAATACTGG	CAGGCGTTTC	GTCAGTATCC	CCGTTTACAG	GGCGGCTTCG	3180
TCTGGGACTG	GGTGGATCAG	TCGCTGATTA	AATATGATGA	AAACGGCAAC	CCGTGGTCGG	3240
CTTACGGCGG	TGATTTTGCC	GATACGCCGA	ACGATCGCCA	GTTCTGTATG	AACGGTCTGG	3300
TCTTTGCCGA	CCGCACGCCG	CATCCAGCGC	TGACGGAAGC	AAAACACCAG	CAGCAGTTTT	3360
TCCAGTTCGG	TTTATCCGGG	CAAACCATCG	AAGTGACCAG	CGAATACCTG	TTCCGTCATA	3420
GCGATAACGA	GTCCTGCAC	TGGATGGTGG	CGCTGGATGG	TAAGCCGCTG	GCAAGCGGTG	3480
AAGTGCTCT	GGATGTCGCT	CCACAAGGTA	AACAGTTGAT	TGAACTGCCT	GAAGTACCGC	3540
AGCCGGAGAG	CGCCGGGCAA	CTCTGGCTCA	CAGTACGCGT	AGTGCAACCG	AACGCGACCG	3600
CATGGTCAGA	AGCCGGGCAC	ATCAGCGCCT	GGCAGCAGTG	GCGTCTGGCG	GAAAACCTCA	3660

GTGTGACGCT	CCCCGCCGCG	TCCCACGCCA	TCCCGCATCT	GACCACCAGC	GAAATGGATT	3720
TTTGCATCGA	GCTGGGTAAT	AAGCGTTGGC	AATTTAACCG	CCAGTCAGGC	TTTCTTTCAC	3780
AGATGTGGAT	TGGCGATAAA	AAACAACGTC	TGACGCGGCT	GCGCGATCAG	TTCACCCGTG	3840
CACCGCTGGA	TAACGACATT	GGCGTAAGTG	AAGCGACCCG	CATTGACCCT	AACGCCTGGG	3900
TCGAACGCTG	GAAGGCGGCG	GGCCATTACC	AGGCCGAAGC	AGCGTTGTTG	CAGTGCACGG	3960
CAGATACACT	TGCTGATGCG	GTGCTGATTA	CGACCGCTCA	CGCGTGGCAG	CATCAGGGGA	4020
AAACCTTATT	TATCAGCCGG	AAAACCTACC	GGATTGATGG	TAGTGGTCAA	ATGGCGATTA	4080
CCGTTGATGT	TGAAGTGGCG	AGCGATACAC	CGCATCCGGC	GCGGATTGGC	CTGAAGTCC	4140
AGCTGGCGCA	GGTAGCAGAG	CGGGTAAACT	GGCTCGGATT	AGGGCCGCAA	GAAAACTATC	4200
CCGACCGCCT	TACTGCCGCC	TGTTTTGACC	GCTGGGATCT	GCCATTGTCA	GACATGTATA	4260
CCCCGTACGT	CTTCCCGAGC	GAAAACGGTC	TGCGCTGCGG	GACGCGCGAA	TTGAATTATG	4320
GCCCCACACCA	GTGGCGCGGC	GACTTCCAGT	TCAACATCAG	CCGCTACAGT	CAACAGCAAC	4380
TGATGGAAAC	CAGCCATCGC	CATCTGCTGC	ACGCGGAAGA	AGGCACATGG	CTGAATATCG	4440
ACGGTTTTCCA	TATGGGGATT	GGTGGCGACG	ACTCCTGGAG	CCCGTCAGTA	TCGGCGGAAT	4500
TACAGCTGAG	CGCCGGTCGC	TACCATTACC	AGTTGGTCTG	GTGTCAAAAA	TAATAATAAC	4560
CGGGCAGGCC	ATGTCTGCCC	GTATTTGCGC	TAAGGAAATC	CATTATGTAC	TATTTAAAAA	4620
ACACAAACTT	TTGGATGTTC	GGTTTATTCT	TTTTCTTTTA	CTTTTTTATC	ATGGGAGCCT	4680
ACTTCCCGTT	TTTCCCGATT	TGGCTACATG	ACATCAACCA	TATCAGCAA	AGTGATACGG	4740
GTATTATTTT	TGCCGCTATT	TCTCTGTTCT	CGCTATTATT	CCAACCGCTG	TTTGGTCTGC	4800
TTTCTGACAA	ACTCGGCCTC	GACTCTAGGC	GGCCGCGGGG	ATCCAGACAT	GATAAGATAC	4860
ATTGATGAGT	TTGGACAAAC	CACAACCTAGA	ATGCAGTGAA	AAAAATGCTT	TATTTGTGAA	4920
ATTTGTGATG	CTATTGCTTT	ATTTGTAACC	ATTATAAGCT	GCAATAAACA	AGTTAACAAC	4980
AACAATTGCA	TTCATTTTAT	GTTTCAGGTT	CAGGGGGAGG	TGTGGGAGGT	TTTTTCGGAT	5040
CCTCTAGAGT	CGAGTAGATA	AGTAGCATGG	CGGGTTAATC	ATTAAGTACA	AGGAACCCCT	5100
AGTGATGGAG	TTGGCCACTC	CCTCTCTGCG	CGCTCGCTCG	CTCACTGAGG	CCGGGCGACC	5160
AAAGGTGCGC	CGACGCCCGG	GCTTTGCCCC	GGCGGCCTCA	GTGAGCGAGC	GAGCGCGCAG	5220
CAGATCTGGA	AGGTGCTGAG	GTACGATGAG	ACCCGCACCA	GGTGCAGACC	CTGCGAGTGT	5280
GGCGGTAAAC	ATATTAGGAA	CCAGCCTGTG	ATGCTGGATG	TGACCGAGGA	GCTGAGGCCC	5340
GATCACTTGG	TGCTGGCCTG	CACCCGCGCT	GAGTTTGGCT	CTAGCGATGA	AGATACAGAT	5400
TGAGGTACTG	AAATGTGTGG	GCGTGGCTTA	AGGGTGGGAA	AGAATATATA	AGGTGGGGGT	5460
CTTATGTAGT	TTTGTATCTG	TTTTGCAGCA	GCCGCCGCCG	CCATGAGCAC	CAACTCGTTT	5520

GATGGAAGCA	TTGTGAGCTC	ATATTTGACA	ACGCGCATGC	CCCCATGGGC	CGGGGTGCGT	5580
CAGAATGTGA	TGGGCTCCAG	CATTGATGGT	CGCCCCGTCC	TGCCCCGAAA	CTCTACTACC	5640
TTGACCTACG	AGACCGTGTC	TGGAACGCCG	TTGGAGACTG	CAGCCTCCGC	CGCCGCTTCA	5700
GCCGCTGCAG	CCACCGCCCC	CGGGATTGTG	ACTGACTTTG	CTTTCCTGAG	CCCCTTGCA	5760
AGCAGTGCAG	CTTCCCGTTC	ATCCGCCCGC	GATGACAAGT	TGACGGCTCT	TTTGGCACAA	5820
TTGGATTCTT	TGACCCGGGA	ACTTAATGTC	GTTTCTCAGC	AGCTGTTGGA	TCTGCGCCAG	5880
CAGGTTTCTG	CCCTGAAGGC	TTCCTCCCTT	CCCAATGCGG	TTTAAACAT	AAATAAAAAA	5940
CCAGACTCTG	TTTGGATTG	GATCAAGCAA	GTGTCTTGCT	GTCTTTATTT	AGGGGTTTTG	6000
CGCGCGCGGT	AGGCCCCGGA	CCAGCGGTCT	CGGTCTTGTA	GGGTCCTGTG	TATTTTTTCC	6060
AGGACGTGGT	AAAGGTGACT	CTGGATGTTT	AGATACATGG	GCATAAGCCC	GTCTCTGGGG	6120
TGGAGGTAGC	ACCACTGCAG	AGCTTCATGC	TGCGGGGTGG	TGTTGTAGAT	GATCCAGTCG	6180
TAGCAGGAGC	GCTGGGCGTG	GTGCCTAAAA	ATGTCTTTCA	GTAGCAAGCT	GATTGCCAGG	6240
GGCAGGCCCT	TGGTGTAAGT	GTTTACAAAG	CGGTTAAGCT	GGGATGGGTG	CATACGTGGG	6300
GATATGAGAT	GCATCTTGGA	CTGTATTTTT	AGGTTGGCTA	TGTTCCCAGC	CATATCCCTC	6360
CGGGGATTCA	TGTTGTGCAG	AACCACCAGC	ACAGTGTATC	CGGTGCACTT	GGGAAATTTG	6420
TCATGTAGCT	TAGAAGGAAA	TGCGTGGAAG	AACTTGGAGA	CGCCCTTGTT	ACCTCCAAGA	6480
TTTTCCATGC	ATTCGTCCAT	AATGATGGCA	ATGGGCCCCAC	GGGCGGCGGC	CTGGGCGAAG	6540
ATATTTCTGG	GATCACTAAC	GTCATAGTTG	TGTTCCAGGA	TGAGATCGTC	ATAGGCCATT	6600
TTTACAAAGC	GCGGGCGGAG	GGTGCCAGAC	TGCGGTATAA	TGGTTCCATC	CGGCCCAGGG	6660
GCGTAGTTAC	CCTCACAGAT	TTGCATTTCC	CACGCTTTGA	GTTCAGATGG	GGGGATCATG	6720
TCTACCTGCG	GGGCGATGAA	GAAAACGGTT	TCCGGGGTAG	GGGAGATCAG	CTGGGAAGAA	6780
AGCAGGTTCC	TGAGCAGCTG	CGACTTACCG	CAGCCGGTGG	GCCCGTAAAT	CACACCTATT	6840
ACCGGGTGCA	ACTGGTAGTT	AAGAGAGCTG	CAGCTGCCGT	CATCCCTGAG	CAGGGGGGCC	6900
ACTTCGTTAA	GCATGTCCCT	GACTCGCATG	TTTTCCCTGA	CCAAATCCGC	CAGAAGGCGC	6960
TCGCCGCCCA	GCGATAGCAG	TTCTTGCAAG	GAAGCAAAGT	TTTTCAACGG	TTGAGACCG	7020
TCCGCCGTAG	GCATGCTTTT	GAGCGTTTGA	CCAAGCAGTT	CCAGGCGGTC	CCACAGCTCG	7080
GTCACCTGCT	CTACGGCATC	TCGATCCAGC	ATATCTCCTC	GTTTCGCGGG	TTGGGGCGGC	7140
TTTCGCTGTA	CGGCAGTAGT	CGGTGCTCGT	CCAGACGGGC	CAGGGTCATG	TCTTTCCACG	7200
GGCGCAGGGT	CCTCGTCAGC	GTAGTCTGGG	TCACGGTGAA	GGGGTGCGCT	CCGGGCTGCG	7260
CGCTGGCCAG	GGTGCGCTTG	AGGCTGGTCC	TGCTGGTGCT	GAAGCGCTGC	CGGTCTTCGC	7320
CCTGCGCGTC	GGCCAGGTAG	CATTTGACCA	TGGTGTGATA	GTCCAGCCCC	TCCGCGGCGT	7380

25

GGCCCTTGGC	GCGCAGCTTG	CCCTTGGAGG	AGGCGCCGCA	CGAGGGGCAG	TGCAGACTTT	7440
TGAGGGCGTA	GAGCTTGGGC	GCGAGAAATA	CCGATTCCGG	GGAGTAGGCA	TCCGCGCCGC	7500
AGGCCCCGCA	GACGGTCTCG	CATTCCACGA	GCCAGGTGAG	CTCTGGCCGT	TCGGGGTCAA	7560
AAACCAGGTT	TCCCCCATGC	TTTTTGATGC	GTTTCTTACC	TCTGGTTTCC	ATGAGCCGGT	7620
GTCCACGCTC	GGTGACGAAA	AGGCTGTCCG	TGTCCCCGTA	TACAGACTTG	AGAGGCCTGT	7680
CCTCGACCGA	TGCCCTTGAG	AGCCTTCAAC	CCAGTCAGCT	CCTTCCGGTG	GGCGCGGGGC	7740
ATGACTATCG	TCGCCGCACT	TATGACTGTC	TTCTTTATCA	TGCAACTCGT	AGGACAGGTG	7800
CCGGCAGCGC	TCTGGGTCAT	TTTCGGCGAG	GACCGCTTTC	GCTGGAGCGC	GACGATGATC	7860
GGCCTGTGCG	TTGCGGTATT	CGGAATCTTG	CACGCCCTCG	CTCAAGCCTT	CGTCACTGGT	7920
CCCCCACCAC	AACGTTTCGG	CGAGAAGCAG	GCCATTATCG	CCGGCATGGC	GGCCGACCGG	7980
CTGGGCTACG	TCTTGCTGGC	GTTGCGGACG	CGAGGCTGGA	TGGCCTTCCC	CATTATGATT	8040
CTTCTCGCTT	CCGGCGGCAT	CGGGATGCCC	GCGTTGCAGG	CCATGCTGTC	CAGGCAGGTA	8100
GATGACGACC	ATCAGGGACA	GCTTCAAGGA	TCGCTCGCGG	CTCTTACCAG	CCTAACTTCG	8160
ATCACTGGAC	CGCTGATCGT	CACGGCGATT	TATGCCGCCT	CGGCGAGCAC	ATGGAACGGG	8220
TTGGCATGGA	TTGTAGGCGC	CGCCCTATAC	CTTGTCTGCC	TCCCCGCGTT	GCGTCGCGGT	8280
GCATGGAGCC	GGGCCACCTC	GACCTGAATG	GAAGCCGGCG	GCACCTCGCT	AACGGATTCA	8340
CCACTCCAAG	AATTGGAGCC	AATCAATTCT	TGCGGAGAAC	TGTGAATGCG	CAAACCAACC	8400
CTTGCCAGAA	CATATCCATC	GCGTCCGCCA	TCTCCAGCAG	CCGCACGCGG	CGCATCTCGG	8460
GCAGCGTTGG	GTCTTGGCCA	CGGGTGCGCA	TGATCGTGCT	CCTGTCTGTTG	AGGACCCGGC	8520
TAGGCTGGCG	GGGTTGCCTT	ACTGGTTAGC	AGAATGAATC	ACCGATACGC	GAGCGAACGT	8580
GAAGCGACTG	CTGCTGCAAA	ACGTCTGCGA	CCTGAGCAAC	AACATGAATG	GTCTTCGGTT	8640
TCCGTGTTTC	GTAAAGTCTG	GAAACGCGGA	AGTCAGCGCC	CTGCACCATT	ATGTTCCGGA	8700
TCTGCATCGC	AGGATGCTGC	TGGCTACCCT	GTGGAACACC	TACATCTGTA	TTAACGAAGC	8760
CTTTCTCAAT	GCTCACGCTG	TAGGTATCTC	AGTTCCGGTG	AGGTCGTTCC	CTCCAAGCTG	8820
GGCTGTGTGC	ACGAACCCCC	CGTTCAGCCC	GACCGCTGCG	CCTTATCCGG	TAACATACGT	8880
CTTGAGTCCA	ACCCGGTAAG	ACACGACTTA	TCGCCACTGG	CAGCAGCCAC	TGGTAACAGG	8940
ATTAGCAGAG	CGAGGTATGT	AGGCGGTGCT	ACAGAGTTCT	TGAAGTGGTG	GCCTAACTAC	9000
GGCTACACTA	GAAGGACAGT	ATTTGGTATC	TGCGCTCTGC	TGAAGCCAGT	TACCTTCGGA	9060
AAAAGAGTTG	GTAGCTCTTG	ATCCGGCAAA	CAAACCACCG	CTGGTAGCGG	TGGTTTTTTT	9120
GTTTGCAAGC	AGCAGATTAC	GCGCAGAAAA	AAAGGATCTC	AAGAAGATCC	TTTGATCTTT	9180
TCTACGGGGT	CTGACGCTCA	GTGGAACGAA	AACTCACGTT	AAGGGATTTT	GGTCATGAGA	9240

26

TTATCAAAAA GGATCTTCAC CTAGATCCTT TTAAATTAAA AATGAAGTTT TAAATCAATC	9300
TAAAGTATAT ATGAGTAAAC TTGGTCTGAC AGTTACCAAT GCTTAATCAG TGAGGCACCT	9360
ATCTCAGCGA TCTGTCTATT TCGTTCATCC ATAGTTGCCT GACTCCCCGT CGTGTAGATA	9420
ACTACGATAC GGGAGGGCTT ACCATCTGGC CCCAGTGCTG CAATGATACC GCGAGACCCA	9480
CGCTCACCGG CTCCAGATTT ATCAGCAATA AACCAGCCAG CCGGAAGGGC CGAGCGCAGA	9540
AGTGGTCTG CAACTTTATC CGCCTCCATC CAGTCTATTA ATTGTTGCCG GGAAGCTAGA	9600
GTAAGTAGTT CGCCAGTTAA TAGTTTGCGC AACGTTGTTG CCATTGCTGC AGGCATCGTG	9660
GTGTCACGCT CGTCGTTTGG TATGGCTTCA TTCAGTCCG GTTCCCAACG ATCAAGGCGA	9720
GTTACATGAT CCCCCATGTT GTGCAAAAAA GCGGTTAGCT CCTTCGGTCC TCCGATCGTT	9780
GTCAGAAGTA AGTTGGCCGC AGTGTATCA CTCATGGTTA TGGCAGCACT GCATAATTCT	9840
CTTACTGTCA TGCCATCCGT AAGATGCTTT TCTGTGACTG GTGAGTACTC AACCAAGTCA	9900
TTCTGAGAAT AGTGTATGCG GCGACCGAGT TGCTCTTGCC CGGCGTCAAC ACGGGATAAT	9960
ACCGCGCCAC ATAGCAGAAC TTTAAAAGTG CTCATCATTG GAAAACGTTT TTCGGGGCGA	10020
AAACTCTCAA GGATCTTACC GCTGTTGAGA TCCAGTTCGA TGTAACCCAC TCGTGACCC	10080
AACTGATCTT CAGCATCTTT TACTTTCACC AGCGTTTCTG GGTGAGCAAA AACAGGAAGG	10140
CAAAATGCCG CAAAAAGGG AATAAGGGCG ACACGGAAAT GTTGAATACT CATACTCTTC	10200
CTTTTTCAAT ATTATTGAAG CATTATCAG GGTTATTGTC TCATGAGCGG ATACATATTT	10260
GAATGTATTT AGAAAAATAA ACAAATAGGG GTTCCGCGCA CATTTCCTCCG AAAAGTGCCA	10320
CCTGACGTCT AAGAAACCAT TATTATCATG ACATTACCT ATAAAAATAG GCGTATCACG	10380
AGGCCCTTTC GTCTTCAA	10398

(2) INFORMATION FOR SEQ ID NO:2:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 20 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: unknown

(ii) MOLECULE TYPE: other nucleic acid

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:2:

TATTTAAGCC CGAGTGAGCT

20

What is claimed is:

1. A method for production of recombinant adeno-associated virus (AAV) comprising the steps of:
 - (a) introducing into a selected host cell a first vector comprising T7 polymerase under control of sequences which drive expression thereof,
 - a second vector comprising AAV rep and cap genes under control of T7 promoter sequences which drive expression of rep and cap; and
 - a third vector comprising from 5' to 3', a cassette consisting essentially of a 5' AAV inverted terminal repeat (ITR), a selected minigene, and a 3' AAV ITR;
 - (b) culturing the host cell under conditions which permit replication and packaging of recombinant AAV; and
 - (c) recovering the recombinant AAV.
2. The method according to claim 1 wherein at least one of the vectors is an adenovirus and the host cell is a 293 cell.
3. The method according to claim 1 wherein the first vector is a recombinant adenovirus.
4. The method according to claim 1 wherein the second vector is a recombinant adenovirus.
5. The method according to claim 1 wherein the third vector further comprises adenoviral sequences flanking the cassette.

6. The method according to any of claims 1 to 5 wherein the minigene contains a transgene which is a marker gene.

7. The method according to claim 6 wherein the minigene contains a transgene which is a therapeutic gene.

8. A method for production of recombinant adeno-associated virus (AAV) comprising the steps of:

(a) providing a host cell which expresses T7 polymerase;

(b) introducing into the host cell a first vector which comprises AAV *rep* and *cap* genes under control of T7 promoter sequences;

(c) introducing into the host cell a second vector comprising a cassette consisting essentially of 5' AAV inverse terminal repeat (ITR), a selected minigene, and 3' AAV ITR; and

(d) culturing the host cell under conditions which permit replication and packaging of a recombinant AAV.

9. The method according to claim 8 wherein step (b) comprises the step of transfecting the host cell with a vector comprising the T7 promoter and the AAV *rep* and *cap* genes.

10. The method according to claim 8 wherein step (b) comprises the step of infecting the host cell with a recombinant adenovirus comprising the T7 promoter sequences, and the AAV *rep* and *cap* genes.

11. The method according to claim 8 wherein step (c) comprises transfecting the host cell with a vector comprising the cassette.

12. The method according to claim 8 wherein step (c) comprises infecting the host cell with a recombinant adenovirus comprising the cassette flanked by adenovirus sequences.

13. A method for production of recombinant adeno-associated virus (AAV) comprising the steps of:

(a) providing a host cell stably transfecting with AAV *rep* and *cap* genes under control of T7 promoter sequences;

(b) introducing into the host cell a vector comprising T7 polymerase;

(c) introducing into the host cell with vector comprising a cassette consisting essentially of a 5' AAV inverse terminal repeat (ITR), a selected minigene, and a 3' AAV ITR; and

(d) culturing the host cell under conditions which permit replication and packaging of a recombinant AAV.

14. The method according to claim 13 wherein step (b) comprises the step of transfecting the host cell with a vector comprising the T7 polymerase gene.

15. The method according to claim 13 wherein step (b) comprises the step of infecting the host cell with a recombinant adenovirus comprising the T7 polymerase gene under control of regulatory sequences controlling expression thereof.

16. The method according to claim 13 wherein step (c) comprises the step of transfecting the host cell with a vector comprising the cassette.

17. The method according to claim 13 wherein step (c) comprises the step of infecting the host cell with a recombinant adenovirus comprising the cassette flanked by adenovirus sequences.

18. A method for production of recombinant adeno-associated virus (AAV) comprising the steps of:

(a) providing a host cell comprising a cassette consisting essentially of 5' AAV inverse terminal repeats (ITR), a selected minigene, and a 3' AAV ITR;

(b) introducing into the host cell a vector comprising AAV rep and cap genes under control of T7 promoter sequences;

(c) introducing into the host cell a vector comprising the T7 polymerase; and

(d) culturing the host cell under conditions which permit replication and packaging of a recombinant AAV.

19. The method according to claim 18 wherein step (b) comprises the step of transfecting the host cell with a plasmid vector.

20. The method according to claim 18 wherein step (b) comprises the step of infecting the host cell with a recombinant adenoviral vector.

21. The method according to claim 18 wherein step (c) comprises the step of transfecting the host cell with a plasmid vector containing the T7 polymerase under control of regulatory sequences which direct expression thereof.

22. The method according to claim 18 wherein step (c) comprises the step of infecting the host cell with a recombinant adenovirus comprising the T7 polymerase under control of regulatory sequences which direct expression thereof.

23. A method for production of recombinant adeno-associated virus (AAV) comprising the steps of:

(a) providing a host cell stably transfected with a cassette consisting essentially of 5' AAV inverse terminal repeats (ITR), a selected minigene, and a 3' AAV ITR and a plasmid comprising AAV rep and cap genes under control of T7 promoter sequences;

(b) introducing into the host cell a vector comprising the T7 polymerase; and

(c) culturing the host cell under conditions which permit replication and packaging of a recombinant AAV.

24. A method for production of recombinant adeno-associated virus (AAV) comprising the steps of;

(a) providing a host cell stably transfected with a cassette consisting essentially of 5' AAV inverse terminal repeats (ITR), a selected minigene, and a 3' AAV ITR and a plasmid comprising T7 polymerase;

(b) introducing into the host cell a vector comprising AAV rep and cap genes under control of T7 promoter sequences; and

(c) culturing the host cell under conditions which permit replication and packaging of a recombinant AAV.

25. A method for production of recombinant adeno-associated virus (AAV) comprising the steps of:

- (a) providing a host cell stably transfected with
 - (i) a cassette consisting essentially of 5' AAV inverse terminal repeats (ITR), a selected minigene, and a 3' AAV ITR;
 - (ii) a plasmid comprising T7 polymerase under control of sequences which regulate expression thereof, said sequences comprising an inducible promoter; and
 - (iii) a plasmid AAV *rep* and *cap* genes under control of T7 promoter sequences; and
- (b) inducing expression of said T7 promoter.

26. A recombinant adenovirus produced according to the method of any one of claims 1 - 25.

1 / 4




FIG. 1

2 / 4




FIG. 2

3/4




FIG. 3

4 / 4




FIG. 4

INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 97/15716

A. CLASSIFICATION OF SUBJECT MATTER

IPC 6 C12N15/86 C12N7/01

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 C12N

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	LEONARD, C. J. ET AL: "Cloning, expression, and partial purification of Rep78: an adeno - associated virus replication protein" VIROLOGY (1994), 200(2), 566-73 CODEN: VIRLAX; ISSN: 0042-6822, 1994, XP002052542 see the whole document ---	26
X	WO 95 13392 A (OHIO MED COLLEGE ;TARGETED GENETICS CORP (US); TREMPER JAMES P (US)) 18 May 1995 see page 8, line 16 - page 9, line 1; claims 1-18 ---	26
X	WO 96 17947 A (TARGETED GENETICS CORP ;ALLEN JAMES M (US)) 13 June 1996 see the whole document ---	26

-/--

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents :

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"8" document member of the same patent family

Date of the actual completion of the international search

19 January 1998

Date of mailing of the international search report

30/01/1998

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Hornig, H

INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 97/15716

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 96 14061 A (CELL GENESYS INC) 17 May 1996 see page 20, line 20 - page 21, line 24 ---	26
X	WO 96 13598 A (UNIV PENNSYLVANIA ; WILSON JAMES M (US); KELLEY WILLIAM M (US); FIS) 9 May 1996 cited in the application see page 2, line 19 - page 22, line 5 ---	26
X	WO 96 12010 A (DEUTSCHES KREBSFORSCH ; MAX PLANCK GESELLSCHAFT (DE); HOELSCHER CHR) 25 April 1996 see the whole document ---	26
X	WO 95 14771 A (US HEALTH ; GENETIC THERAPY INC (US)) 1 June 1995 see the whole document ---	26
X	WO 95 13365 A (TARGETED GENETICS CORP ; UNIV JOHNS HOPKINS (US); FLOTTE TERENCE R) 18 May 1995 see the whole document ---	26
X	WO 94 13788 A (UNIV PITTSBURGH) 23 June 1994 see the whole document ---	26
X	CLARK K R ET AL: "CELL LINES FOR THE PRODUCTION OF RECOMBINANT ADENO-ASSOCIATED VIRUS" HUMAN GENE THERAPY, vol. 6, no. 10, 1 October 1995, pages 1329-1341, XP000569718 see the whole document ---	26
X	KOTIN R M: "PROSPECTS FOR THE USE OF ADENO-ASSOCIATED VIRUS AS A VECTOR FOR HUMAN GENE THERAPY" HUMAN GENE THERAPY, vol. 5, 1994, pages 793-801, XP000651491 cited in the application see the whole document ---	26
A	WO 94 26911 A (UNIV OHIO) 24 November 1994 see the whole document ---	1-26
A	WO 91 00905 A (US ARMY) 24 January 1991 see the whole document ---	1-26
	-/--	

INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 97/15716

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	A. LIEBER ET AL.: "High level gene expression in mammalian cells by a nuclear T7-phage RNA polymerase" NUCLEIC ACIDS RESEARCH, vol. 17, no. 21, - 1989 IRL PRESS LIMITED, OXFORD, ENGLAND, pages 8485-8493, XP002052543 cited in the application see the whole document ---	1-26
A	FUERST T R ET AL: "EUKARYOTIC TRANSIENT-EXPRESSION SYSTEM BASED ON RECOMBINANT VACCINIA VIRUS THAT SYNTHESIZES BACTERIOPHAGE T7 RNA POLYMERASE" PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, vol. 83, no. 21, 1 November 1986, pages 8122-8126, XP000563743 cited in the application see the whole document ---	1-26
A	ELROY-STEIN O ET AL: "CYTOPLASMIC EXPRESSION SYSTEM BASED ON CONSTITUTIVE SYNTHESIS OF BACTERIOPHAGE T7 POLYMERASE IN MAMMALIAN CELLS" PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, vol. 87, no. 17, 1 September 1990, pages 6743-6747, XP000563742 cited in the application see the whole document ---	1-26
P,X	WO 97 00947 A (RHONE POULENC RORER SA ;LATTA MARTINE (FR); ORSINI CECILE (FR); PE) 9 January 1997 see the whole document -----	26

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 97/15716

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9513392 A	18-05-95	AU 678867 B AU 8130994 A EP 0728214 A JP 9510602 T	12-06-97 29-05-95 28-08-96 28-10-97
WO 9617947 A	13-06-96	AU 4596396 A CA 2207927 A EP 0796339 A	26-06-96 13-06-96 24-09-97
WO 9614061 A	17-05-96	AU 4109296 A CA 2204357 A EP 0797436 A	31-05-96 17-05-96 01-10-97
WO 9613598 A	09-05-96	AU 4405596 A EP 0797678 A	23-05-96 01-10-97
WO 9612010 A	25-04-96	DE 4436665 A DE 4436664 A CA 2202664 A EP 0785991 A	18-04-96 04-07-96 25-04-96 30-07-97
WO 9514771 A	01-06-95	US 5693531 A CA 2176600 A EP 0736092 A JP 9505480 T	02-12-97 01-06-95 09-10-96 03-06-97
WO 9513365 A	18-05-95	AU 1129395 A CA 2176117 A EP 0733103 A JP 9509564 T US 5658776 A	29-05-95 18-05-95 25-09-96 30-09-97 19-08-97
WO 9413788 A	23-06-94	US 5478745 A EP 0673415 A JP 8504102 T	26-12-95 27-09-95 07-05-96
WO 9426911 A	24-11-94	US 5591601 A AU 6949894 A CA 2162867 A EP 0751998 A	07-01-97 12-12-94 24-11-94 08-01-97

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 97/15716

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9426911 A		JP 8510132 T	29-10-96
WO 9100905 A	24-01-91	US 5135855 A	04-08-92
		AT 157701 T	15-09-97
		AU 642657 B	28-10-93
		AU 6034490 A	06-02-91
		CA 2063427 A	08-01-91
		DE 69031389 D	09-10-97
		EP 0484374 A	13-05-92
		JP 2525289 B	14-08-96
		JP 5501048 T	04-03-93
		US 5126251 A	30-06-92
WO 9700947 A	09-01-97	FR 2735789 A	27-12-96
		AU 6363996 A	22-01-97